FP11.6 Injectable Autologous Chondrocyte Transplantation for Acetabular Cartilage Defects in Femoroacetabular Impingement: Results from the German Cartilage Registry (DGOU)

Clicks: 12
ID: 331364
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #248 of 444 articles by views in Journal of hip preservation surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 444 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract ICLB11 - The Biologic Arsenal: Essential Cartilage Repair and Orthobiologics in Early Osteoarthritis, Session Room 12 (BMCC Level 3), October 9, 2026, 10:30 - 12:30 Purpose To evaluate mid-term outcomes of injectable matrix-associated autologous chondrocyte transplantation (MACT) for acetabular cartilage defects in femoroacetabular impingement (FAI), comparing two different ACT products (NOVOCART® Inject vs. Chondrosphere®) using data from the German Cartilage Registry. Methods This retrospective analysis included 91 FAI patients (mean age 31.5 years) with isolated ICRS grade 3 or 4 acetabular cartilage defects treated arthroscopically with either NOVOCART® Inject (n=48) or Chondrosphere® (n=43). Clinical outcomes were assessed using the International Hip Outcome Tool (iHOT33) and Visual Analog Scale (VAS) for pain at 6, 12, 24, 36, and 60 months. Clinically important outcome values (MCID, PASS, SCB) were calculated at 36 months. Subgroup analysis compared defect severity (ICRS grade 3 vs. 4) and product-specific outcomes. Results Significant improvement in hip function (iHOT33) was observed across all follow-up time points (p<0.01). Both treatment groups improved similarly with no significant differences in iHOT33 scores. Chondrosphere® showed statistically significant pain reduction (VAS) over time (p<0.01), while NOVOCART® Inject did not reach significance despite similar trends. Patients with ICRS grade 3 defects had superior outcomes at 12 months in both pain and function compared to those with grade 4 lesions. Conclusion Arthroscopic MACT yields sustained improvements in pain and function over 5 years in FAI patients with acetabular cartilage defects. Both hydrogel-based and spheroid-based MACT products demonstrate comparable functional outcomes. However, pain relief appears more pronounced with Chondrosphere®. Earlier intervention in less advanced cartilage damage (ICRS grade 3) is associated with better results, emphasizing the need for timely surgical management to prevent defect progression.
Reference Key
openalex_W7220450078 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Med Habil Moritz Riedl, med habil Wolfram Steens, Drmed habil Ingo Banke, Stefan Landgraeber, med Steffen Thier, med Wolfgang Zinser, med habil Stefan Fickert
Are you one of these authors? Claim your profile
Journal Journal of hip preservation surgery
Year 2026
DOI
10.1093/jhps/hnag043.086
URL
https://doi.org/10.1093/jhps/hnag043.086
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.